DUSA
Davis Select U.S. Equity ETF
stock BATS ETF

If you aren’t watching the $LEXX chart right now, you’re missing a textbook "coiled spring" setup. While the shorts are busy throwing FUD at the wall to see what sticks, the tape is telling a much more bullish story.
The Technical Setup: Crossing the Rubicon
Looking at the current daily chart, we are on the verge of a massive trend reversal.
• The 100-Day SMA Cross: The price is currently hammering against the 100-day Simple Moving Average (SMA). In technical analysis, a clean break and hold above this level often signals the end of a consolidation phase and the start of a parabolic run.
• MACD & RSI Momentum: The MACD is curling upward for a bullish crossover, and the RSI has reset from overbought levels, leaving plenty of "white space" for a run toward the $1.20–$1.50 range.
• The Short Squeeze Factor: With a reported 373k shares short and "Days to Cover" sitting between 2.3 and 3.7, any spike in volume—like a move over the 100-day—will force shorters into a crowded exit. When the "Smart Money" (like UBS, who recently increased their position by 4,900%) starts buying, the shorts are officially trapped.
The Fundamental "End-Game": The One-Yard Line
The technicals are the "how," but the fundamentals are the "why." Lexaria isn't just a biotech; it's a validated delivery platform (DehydraTECH) on the verge of an exit.
• The "Closer" CEO: Management brought in Richard Christopher, the man who served as CFO during the $230M sale of DUSA Pharmaceuticals to Sun Pharma. You don't hire a "closer" unless you have a deal to close.
• The Bunka Gift: Chairman Chris Bunka just gifted 100,000 shares back to the treasury for free. In the micro-cap world, this "cap table cleanup" reduces dilution and "greases the wheels" for a buyer. Insiders don't give away equity if they expect a crash; they do it to make the company a prettier target for a buyout.
• The April 30th Deadline: The Material Transfer Agreement (MTA) with a global "PharmaCO" expires in 30 days. The partner has the human data; now they have to sign or get off the pot.
Revolutionary Results: The "Needle Killer"
• 20x Sustain: Human studies prove DehydraTECH maintains blood-glucose lowering effects nearly 20x better than standard oral versions at the 24-hour mark.
• Hypertension & GLP-1: It turns painful weight-loss injections into a pill with 50% fewer side effects.
The Bottom Line: It’s times like this when you need to focus on the facts, not the FUD. We have a technical breakout, a "buyout" CEO, and a hard deadline on April 30th.

If you aren’t watching the $LEXX chart right now, you’re missing a textbook "coiled spring" setup. While the shorts are busy throwing FUD at the wall to see what sticks, the tape is telling a much more bullish story.
The Technical Setup: Crossing the Rubicon
Looking at the current daily chart, we are on the verge of a massive trend reversal.
• The 100-Day SMA Cross: The price is currently hammering against the 100-day Simple Moving Average (SMA). In technical analysis, a clean break and hold above this level often signals the end of a consolidation phase and the start of a parabolic run.
• MACD & RSI Momentum: The MACD is curling upward for a bullish crossover, and the RSI has reset from overbought levels, leaving plenty of "white space" for a run toward the $1.20–$1.50 range.
• The Short Squeeze Factor: With a reported 373k shares short and "Days to Cover" sitting between 2.3 and 3.7, any spike in volume—like a move over the 100-day—will force shorters into a crowded exit. When the "Smart Money" (like UBS, who recently increased their position by 4,900%) starts buying, the shorts are officially trapped.
The Fundamental "End-Game": The One-Yard Line
The technicals are the "how," but the fundamentals are the "why." Lexaria isn't just a biotech; it's a validated delivery platform (DehydraTECH) on the verge of an exit.
• The "Closer" CEO: Management brought in Richard Christopher, the man who served as CFO during the $230M sale of DUSA Pharmaceuticals to Sun Pharma. You don't hire a "closer" unless you have a deal to close.
• The Bunka Gift: Chairman Chris Bunka just gifted 100,000 shares back to the treasury for free. In the micro-cap world, this "cap table cleanup" reduces dilution and "greases the wheels" for a buyer. Insiders don't give away equity if they expect a crash; they do it to make the company a prettier target for a buyout.
• The April 30th Deadline: The Material Transfer Agreement (MTA) with a global "PharmaCO" expires in 30 days. The partner has the human data; now they have to sign or get off the pot.
Revolutionary Results: The "Needle Killer"
• 20x Sustain: Human studies prove DehydraTECH maintains blood-glucose lowering effects nearly 20x better than standard oral versions at the 24-hour mark.
• Hypertension & GLP-1: It turns painful weight-loss injections into a pill with 50% fewer side effects.
The Bottom Line: It’s times like this when you need to focus on the facts, not the FUD. We have a technical breakout, a "buyout" CEO, and a hard deadline on April 30th.